TriPath Imaging, Inc.

Study demonstrates prognostic value of TriPath Imaging assay

Published in Medical Imaging Week, July 10th, 2004

TriPath Imaging, Inc., (TPTH) announced the presentation of an independent study at the 40th annual meeting of the American Society of Clinical Oncology on the prognostic utility of Melastatin gene expression in primary melanoma lesions.

The study measured Melastatin expression using TriPath Imaging's new chromogenic, in-situ hybridization (CISH) method and demonstrated loss of Melastatin expression was an independent prognostic indicator for overall survival in primary melanoma.

This research study's objective was to evaluate the new CISH method developed by TriPath Oncology, a wholly owned subsidiary of TriPath Imaging, for determining Melastatin...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Imaging Week

Source: Medical Imaging Week (2004-07-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry